Literature DB >> 2544284

The kinetics of 14C-GR43175 in rat and dog.

F A Dallas1, C M Dixon, R J McCulloch, D A Saynor.   

Abstract

GR43175 is a selective 5-HT 1-like receptor agonist which is effective in the acute treatment of migraine. Rats and dogs were dosed intravenously (iv) and orally (po) with 1 mg 14C-GR43175 base (as succinate salt)/kg bodyweight. GR43175 is rapidly absorbed after oral dosing. In dog, 95-100% of the dose is absorbed, but less (25-30%) is absorbed by the rat. The bioavailability is greater than 54% in dog, but lower in rat. Except for the CNS, drug-related material is widely distributed after iv dosing, but is mainly concentrated in the gastrointestinal tract and excretory organs after oral dosing. GR43175 is eliminated from plasma by a combination of renal and metabolic clearance. Some first-pass metabolism occurs in both species. In dog the major route of excretion is in urine (78-83% of the dose) after either route of administration. In rat, urine is also the major route of excretion (71%) after iv dosing. After oral dosing to the rat the major route of excretion is in the faeces (83%). GR43175 is extensively metabolized, after either route of administration, in both species. GR49336, the indole acetic acid derivative of GR43175, is the major metabolite in dog and a major metabolite in rat.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2544284     DOI: 10.1111/J.1468-2982.1989.TB00073.X

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  9 in total

1.  Actions of non-peptide ergot alkaloids at 5-HT1-like and 5-HT2 receptors mediating vascular smooth muscle contraction.

Authors:  S J MacLennan; G R Martin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-08       Impact factor: 3.000

Review 2.  Rationale for the use of 5-HT1-like agonists in the treatment of migraine.

Authors:  W Feniuk; P P Humphrey; M J Perren; H E Connor; E T Whalley
Journal:  J Neurol       Date:  1991       Impact factor: 4.849

Review 3.  Pharmacology of antimigraine drugs.

Authors:  P R Saxena; M O Den Boer
Journal:  J Neurol       Date:  1991       Impact factor: 4.849

4.  Mixed effect modeling of sumatriptan pharmacokinetics during drug development. I: Interspecies allometric scaling.

Authors:  V F Cosson; E Fuseau; C Efthymiopoulos; A Bye
Journal:  J Pharmacokinet Biopharm       Date:  1997-04

5.  Carotid vascular effects of ergotamine and dihydroergotamine in the pig: no exclusive mediation via 5-HT1-like receptors.

Authors:  M O den Boer; J P Heiligers; P R Saxena
Journal:  Br J Pharmacol       Date:  1991-09       Impact factor: 8.739

6.  Neuroendocrine effects of sumatriptan.

Authors:  J R Herdman; N J Delva; R E Hockney; G M Campling; P J Cowen
Journal:  Psychopharmacology (Berl)       Date:  1994-01       Impact factor: 4.530

7.  Activity of botulinum toxin type A in cranial dura: implications for treatment of migraine and other headaches.

Authors:  Zdravko Lacković; Boris Filipović; Ivica Matak; Zsuzsanna Helyes
Journal:  Br J Pharmacol       Date:  2016-01       Impact factor: 8.739

Review 8.  Sumatriptan. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the acute treatment of migraine and cluster headache.

Authors:  K L Dechant; S P Clissold
Journal:  Drugs       Date:  1992-05       Impact factor: 9.546

Review 9.  Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache.

Authors:  G L Plosker; D McTavish
Journal:  Drugs       Date:  1994-04       Impact factor: 9.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.